Summary & Overview
HCPCS Level II J1730: Injection, Diazoxide, up to 300 mg
HCPCS Level II code J1730 denotes a single dose of diazoxide (up to 300 mg) administered by injection. Diazoxide is used for rapid correction of severe hypoglycemia in select clinical situations, making this code relevant to acute care, emergency medicine, and inpatient pharmacotherapy. National attention to J1730 centers on appropriate use, site-of-service billing distinctions, and payer coverage policies for parenteral antihypoglycemic therapy.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, typical sites of service, and the clinical context for diazoxide injection. The publication summarizes common payer coverage considerations and what to expect in billing practice, and it highlights available benchmarks and policy updates when present. Where specific data elements were not provided in the input, the report notes that information is not available.
This overview is intended for billing managers, clinical coders, hospital pharmacists, and policy analysts seeking a national-level understanding of HCPCS Level II code J1730, its clinical application, and the payer landscape that affects reimbursement and utilization in acute care settings.
Billing Code Overview
HCPCS Level II code J1730 represents Injection, diazoxide, up to 300 mg. The code describes a single injectable administration of the antihypoglycemic agent diazoxide, indicated for acute management of hypoglycemia in certain clinical contexts.
Service type: Medication administration (injectable therapeutic agent)
Typical site of service: Hospital inpatient or outpatient settings, emergency department, and other acute care environments where parenteral administration is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with persistent hypoglycemia due to hyperinsulinemic states such as congenital hyperinsulinism, sulfonylurea overdose, or insulinoma where oral therapies have failed or are contraindicated. The patient presents to an inpatient pediatric endocrine unit or an adult medical ward with recurrent symptomatic hypoglycemia (neuroglycopenic symptoms, seizures, or documented glucose <50 mg/dL) despite dextrose infusion and dietary measures. Diazoxide is ordered as an intravenous or oral anti-hypoglycemic agent; billing for J1730 (injection, diazoxide, up to 300 mg) is generated when diazoxide is supplied and administered in the facility.
Clinical workflow: On evaluation, the endocrine team documents the indication, baseline metabolic and cardiac monitoring (including blood glucose and blood pressure), and a plan for diazoxide dosing. Pharmacy compounds or dispenses diazoxide and labels the vial; nursing performs medication administration and documents dose, route, and patient response. Follow-up includes serial glucose checks, vital signs for hypertension or fluid retention, and adjustment of dose; inpatient billing staff records J1730 for the supplied injectable diazoxide per 300 mg increment and appends applicable modifiers reflecting service circumstances and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |